Immunohistochemistry detected a positive expression of hnRNPA2/B1 in 56.5% of primary invasive breast cancers and 9.7% of normal breast tissues, thus supporting the use of hnRNPA2/B1 as a clinical breast cancer diagnostic biomarker [123]. This evidence concerns the gene HNRNPA2B1 and breast carcinoma.